Carisma Therapeutics (CARM) Earnings Date, Estimates & Call Transcripts $0.99 +0.02 (+2.01%) (As of 03:42 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Carisma Therapeutics Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 14EstimatedActual EPS (Aug. 8) -$0.27 Beat By $0.09 Consensus EPS (Aug. 8) -$0.36 Carisma Therapeutics posted Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.27, which beat the consensus estimate of -$0.36 by $0.09. Quarterly revenue was reported to be $9.20 million, above the consensus estimate of $3.65 million. With a trailing EPS of -$1.78, Carisma Therapeutics' earnings are expected to remain at ($1.43) per share in the coming year. CARM Upcoming EarningsCarisma Therapeutics' next earnings date is estimated for Thursday, November 14, 2024, based off prior year's reporting schedules. Get Carisma Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCARM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CARM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Unstoppable ProsperityCharles Payne Wants You Prepared for Q4Charles Payne Wants You Prepared for Q4 Because as we look toward 2025, there's no denying that market volatility, inflation, and recession fears are top of mind for every investor Now more than ever, it's crucial to have a solid plan for navigating uncertainty and coming out ahead. Click here to secure your seat now. Carisma Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.47-$0.26-$0.37Q2 20242-$0.45-$0.27-$0.36Q3 20242-$0.43-$0.29-$0.36Q4 20242-$0.47-$0.26-$0.37FY 20248-$1.82-$1.08-$1.45Q1 20251-$0.48-$0.48-$0.48Q2 20251-$0.50-$0.50-$0.50Q3 20251-$0.54-$0.54-$0.54Q4 20251-$0.56-$0.56-$0.56FY 20254($2.08)($2.08)($2.08) Carisma Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/8/2024--$0.36-$0.27+$0.09-$0.27$3.65M$9.20M5/9/2024Q1 2024-$0.37-$0.46 -$0.09-$0.46$3.90M$3.40M 4/1/2024Q4 2023--$0.52 -$0.52-$0.52$4.00M$4.29M11/9/2023Q3 2023-$0.60-$0.53+$0.07-$0.53-$3.83M8/10/2023Q2 2023-$0.66-$0.49+$0.17-$0.49-$3.56M5/11/2023Q1 2023--$1.93 -$1.93-$1.93-$3.24M Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022-$2.20-$0.80+$1.40-$0.80--11/7/2022Q3 2022-$1.60$2.80+$4.40$3.60-$0.04M Carisma Therapeutics Earnings - Frequently Asked Questions When is Carisma Therapeutics's earnings date? Carisma Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on CARM's earnings history. Did Carisma Therapeutics beat their earnings estimates last quarter? In the previous quarter, Carisma Therapeutics (NASDAQ:CARM) reported ($0.27) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.36) by $0.09. Learn more on analysts' earnings estimate vs. CARM's actual earnings. How much revenue does Carisma Therapeutics generate each year? Carisma Therapeutics (NASDAQ:CARM) has a recorded annual revenue of $14.92 million. How much profit does Carisma Therapeutics generate each year? Carisma Therapeutics (NASDAQ:CARM) has a recorded net income of -$86.88 million. CARM has generated -$1.78 earnings per share over the last four quarters. What is Carisma Therapeutics's EPS forecast for next year? Carisma Therapeutics's earnings are expected to stay at ($1.43) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies XGN Earnings Results CTSO Earnings Results TXMD Earnings Results AWH Earnings Results SNSE Earnings Results BIVI Earnings Results ADVM Earnings Results ACTU Earnings Results SCLX Earnings Results NKTX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending Charles Payne Wants You Prepared for Q4 (Ad)Charles Payne Wants You Prepared for Q4 Because as we look toward 2025, there's no denying that market volatility, inflation, and recession fears are top of mind for every investor Now more than ever, it's crucial to have a solid plan for navigating uncertainty and coming out ahead. Click here to secure your seat now. This page (NASDAQ:CARM) was last updated on 11/1/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredCapitalize on Generational Opportunities in the ‘Roaring 2020s’The industrial revolutions in our country's past have connected the world in ways never thought possible… C...Unstoppable Prosperity | SponsoredIf You’re Even Thinking of Investing in AI, Read This First.If you're starting to invest in AI or even just thinking about it, it can feel overwhelming and even a bit sca...Brownstone Research | Sponsored4 Trades for $4?! (Next Pick Goes LIVE Tues!)Bryan wants show you his unique trading philosophy... It allows his members to take profits early again and...Monument Traders Alliance | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts